News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072003

2018 Archives

Nov 9, 2018
New Efficacy, Safety and Biomarker Data Presented for Stage IV I-O Naïve Melanoma Patients in PIVOT-02 Study of NKTR-214 with nivolumab

Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical and preclinical data for its I-O pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting....

More
Nov 7, 2018

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2018. Cash and investments in marketable securities at September 30, 2018 were...

More
Nov 6, 2018

Nektar Therapeutics (NASDAQ:NKTR) announced that it has entered into an oncology clinical collaboration with Pfizer Inc. (NYSE:PFE) to evaluate several combination regimens in multiple cancer...

More
Nov 6, 2018

Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with melanoma specialists and company management on Saturday, November 10, 2018 at...

More
Oct 30, 2018

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 7, 2018, after the close of U.S.-based financial markets. Howard Robin,...

More
Oct 2, 2018

Nektar Therapeutics (Nasdaq: NKTR) today announced that ten clinical and preclinical data presentations across its immuno-oncology portfolio will be presented at the upcoming Society for...

More
Oct 1, 2018

Nektar Therapeutics (Nasdaq: NKTR) today announced that it has appointed Karin Eastham as an independent director to its Board of Directors. Ms. Eastham brings more than 35 years of experience as...

More
Aug 8, 2018

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2018. Cash and investments in marketable securities at June 30, 2018 were $2.1 billion...

More
Aug 1, 2018

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Wednesday, August 8, 2018, after the close of U.S.-based financial markets. Howard Robin, president...

More
Jul 30, 2018
NKTR-181 is a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy

Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review the company's New Drug Application (NDA) for NKTR-181 for the...

More
Jun 14, 2018

Nektar Therapeutics (Nasdaq: NKTR) today announced that new clinical and preclinical data for NKTR-181 were presented this week at the 80th Annual Scientific Meeting of the College on Problems of...

More
Jun 5, 2018

Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the upcoming Jefferies 2018 Healthcare Conference in...

More
Jun 2, 2018
Data from the Phase 1 dose-escalation and early data from the Phase 2 dose expansion phase of the ongoing PIVOT study highlighted as an oral presentation

Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced presentation of preliminary data from the ongoing PIVOT Phase 1/2 Study, which is evaluating the combination...

More
May 31, 2018

Nektar Therapeutics (Nasdaq: NKTR) today announced submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for NKTR-181, a new molecular entity (NME) and the...

More
May 16, 2018
Abstract presentations highlight potential of NKTR-214 to be combined with multiple I-O and targeted mechanisms in the treatment of cancer

Nektar Therapeutics (Nasdaq: NKTR) today announced that new clinical and preclinical data will be presented at the upcoming 2018 American Society of Clinical Oncology Annual Meeting, which is...

More
May 10, 2018

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2018. Cash and investments in marketable securities at March 31, 2018 were $333.8...

More
May 8, 2018

Nektar Therapeutics (NASDAQ: NKTR) today announced that it has commenced dosing patients with systemic lupus erythematosus (SLE) in a Phase 1b clinical study evaluating NKTR-358, a first-in-class...

More
May 3, 2018

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 10, 2018, after the close of U.S.-based financial markets. Howard Robin, president and...

More
Apr 30, 2018

Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host an analyst and investor event with clinical investigators on Saturday, June 2, 2018 at 6:45 p.m. CDT in Chicago, IL during the...

More
Apr 24, 2018
New collaboration to explore the potential clinical benefits of two novel and complementary immuno-oncology mechanisms

Nektar Therapeutics (NASDAQ:NKTR) announced today that it has entered into a new clinical collaboration with Takeda Pharmaceutical Company Limited to evaluate Nektar's investigational medicine,...

More
Apr 15, 2018
Four Preclinical Data Presentations Showcase Nektar's Immuno-Oncology Programs, NKTR-214 and NKTR-262

Nektar Therapeutics (Nasdaq: NKTR) today announced that it is presenting new preclinical data for its immuno-oncology programs at the American Association for Cancer Research (AACR) Annual Meeting...

More
Apr 11, 2018
Combination regimen designed to engage both the body's innate and adaptive immune response to fight cancer

Nektar Therapeutics (Nasdaq: NKTR) today announced that it has initiated dosing patients in the Phase 1/2 REVEAL clinical study evaluating the efficacy and safety of the combination of...

More
Apr 3, 2018

Nektar Therapeutics (Nasdaq: NKTR) announced today that the waiting period has expired under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the previously-announced Strategic...

More
Mar 7, 2018

Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the upcoming Cowen and Company 38th Annual Health Care...

More
Mar 1, 2018

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2017. Cash and investments in marketable securities at December 31, 2017 were

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide